Allakos Stock (NASDAQ:ALLK)
Previous Close
$0.68
52W Range
$0.63 - $3.41
50D Avg
$0.79
200D Avg
$1.40
Market Cap
$56.49M
Avg Vol (3M)
$566.93K
Beta
1.15
Div Yield
-
ALLK Company Profile
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
ALLK Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| ARVN | Arvinas, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| ATRA | Atara Biotherapeutics, Inc. |
| NXTC | NextCure, Inc. |
| FATE | Fate Therapeutics, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| RCUS | Arcus Biosciences, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| GTHX | G1 Therapeutics, Inc. |
| HRTX | Heron Therapeutics, Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| CRBU | Caribou Biosciences, Inc. |
| ALLO | Allogene Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| ANNX | Annexon, Inc. |
| NLTX | Neurogene Inc. |
| KURA | Kura Oncology, Inc. |
| KRTX | Karuna Therapeutics, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |